Increased in vitro antimicrobial resistance of Mycoplasma pneumoniae isolates obtained from children in Beijing, China, in 2023
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1478087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Xinyu Jia und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China. Hauptthemen laut MEDLINE: Mycoplasma pneumoniae, Microbial Sensitivity Tests, Pneumonia, Mycoplasma, Anti-Bacterial Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Mycoplasma pneumoniae ( M. pneumoniae ), a common pathogen of community-acquired pneumonia in school-age children and adolescents, can cause epidemics worldwide. In late 2023, the incidence of M. pneumoniae infection among children reached a high level.
Methods
We investigated the in vitro antimicrobial susceptibility of 62 M. pneumoniae isolates obtained from children with pneumonia in Beijing between 2021 and 2023, and analyzed the correlation of antimicrobial susceptibility with molecular characteristics of isolates and clinical manifestations of patients.
Results
The resistance rates of M. pneumoniae isolates against erythromycin and azithromycin were both 100% (62/62). The minimum inhibitory concentration (MIC) of acetylspiramycin (16-membered macrolides) was lower than that of erythromycin and azithromycin. The MIC of azithromycin in 2023 was notably higher compared to 2021 and 2022. No resistance to tetracycline and levofloxacin was observed. Genotypes P1 type 1 and P1 type 2 were identified in 74.2% and 25.8% of isolates, and M4-5-7-2 (61.3%) and M3-5-6-2 (22.6%) were predominant multi-locus variable-number tandem-repeat analysis (MLVA) types. The A2063G mutation was present in all isolates (100%). Among the patients, 45/59 cases (76.3%) had severe M. pneumoniae pneumonia, and 14/59 cases (23.7%) presented co-infection. The duration of fever was 12 days (1-30 days) and the fever duration after initiation of macrolide antibiotics treatment was 8 days (1-22 days).
Discussion
Our study showed that macrolide-resistant M. pneumoniae (MRMP) with high in vitro antimicrobial resistance level may be the causative factor of the M. pneumoniae epidemic in late 2023 in Beijing, China. It is urgent to pay more attention to MRMP and the antibiotics choose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China.
- Department of Allergy, Children's Hospital of Capital Institute of Pediatrics, Beijing, China.
Zitieren
APA
Jia, X., Chen, Y., Gao, Y., Ren, X., Du, B., Zhao, H., Feng, Y., Xue, G., Cui, J., Gan, L., Feng, J., Fan, Z., Fu, T., Xu, Z., Yu, Z., Yang, Y., Zhao, S., Huang, L., Ke, Y., …, & Yuan, J. (2024). Increased in vitro antimicrobial resistance of Mycoplasma pneumoniae isolates obtained from children in Beijing, China, in 2023. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1478087
Vancouver
Jia X, Chen Y, Gao Y, Ren X, Du B, Zhao H, et al. Increased in vitro antimicrobial resistance of Mycoplasma pneumoniae isolates obtained from children in Beijing, China, in 2023. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1478087
BibTeX
@article{Jia2024,
author = {Jia, Xinyu and Chen, Yujie and Gao, Yagang and Ren, Xue and Du, Bing and Zhao, Hanqing and Feng, Yanling and Xue, Guanhua and Cui, Jinghua and Gan, Lin and Feng, Junxia and Fan, Zheng and Fu, Tongtong and Xu, Ziying and Yu, Zihui and Yang, Yang and Zhao, Shuo and Huang, Lijuan and Ke, Yuehua and Liu, Chuanhe and Yan, Chao and Yuan, Jing},
title = {Increased in vitro antimicrobial resistance of Mycoplasma pneumoniae isolates obtained from children in Beijing, China, in 2023},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1478087}
}
EUVIMED